CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sanochemia Pharmazeutika AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sanochemia Pharmazeutika AG
Boltzmanngasse 11
Phone: +43 131914560p:+43 131914560 Wien, 1090  Austria Fax: +43 13191456344f:+43 13191456344
Filed for Reorganization Proceedings on 12/16/2019
On 12/16/2019, Sanochemia Pharmazeutika AG filed an Insolvency Petition with the Vienna Commercial Court for the initiation of a Reorganization Procedure without self administration.
This company is no longer actively traded on any major stock exchange.
Business Summary
Sanochemia Pharmazeutika AG is an Austrian pharmaceutical company focused on the development and manufacture of drugs and diagnostics in neurodegeneration, pain and oncology areas, among others, as well as diagnostics based on contrast media. It operates through three main business divisions and the Production Division, which acts on behalf of those business divisions or on a contract manufacturing basis. The Production Division is engaged in the synthesis of active pharmaceutical substances (APIs), drug formulation and pharmaceutical production. The Human Pharmaceuticals Division is primarily responsible for the Company's diagnostic activities. The Research and Development Division is responsible for the Company's development activities. The Veterinary Pharmaceuticals Division comprises a portfolio of veterinary medical product and distribution channels in the CEE markets, Middle East and South-East Asia. The Company's shareholders are Inphasearch AG and Invesa AG, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20199/30/2018Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairwoman of the Supervisory Board EvelineFrantsits 4/5/2013
Chairman of the Management Board, Chief Executive Officer ..Abrahamsberg 10/1/2016 10/1/2016
Deputy Chairman of the Supervisory Board Johannes M.Respondek 5/21/2013 1/26/2004
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Alvetra GmbH
SAC
Sanochemia Pharmazeutika AG
Slo-Werfft s.r.o.
Werfft Spol s.r.o.
Werfft-Pharma Kft.

General Information
Number of Employees: 152 (As of 3/31/2019)
Outstanding Shares: 15,649,831 (As of 5/6/2019)
Shareholders: 9,488
Stock Exchange: WBAG
Fax Number: +43 13191456344


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023